- Home
- SITC vs IMUX Comparison
SITC vs IMUX Comparison
Compare SITC & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITC | IMUX |
|---|---|---|
| Founded | 1965 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.8M | 155.8M |
| IPO Year | 1994 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SITC | IMUX |
|---|---|---|
| Price | $3.74 | $7.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $43.09 |
| AVG Volume (30 Days) | ★ 2.1M | 382.7K |
| Earning Date | 11-02-2026 | 11-12-2026 |
| Dividend Yield | ★ 106.95% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,649,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.80 | $0.51 |
| 52 Week High | $8.91 | $17.43 |
Technical Indicators
Market Signals| Indicator | SITC | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 72.09 | 36.21 |
| Support Level | $2.89 | $6.35 |
| Resistance Level | $4.55 | $8.60 |
| Average True Range (ATR) | 0.13 | 0.65 |
| MACD | 0.07 | 0.19 |
| Stochastic Oscillator | 88.56 | 46.67 |
Price Performance
Historical ComparisonAbout SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing, and managing shopping centers.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.